Arbaclofen

DB08891InvestigationalSmall molecule

Arbaclofen, or STX209, is the R-enantiomer of baclofen. It is believed to be a selective gamma-amino butyric acid type B receptor agonist, and has been investigated as a treatment for... It has also been investigated as a treatment for spasticity due to multiple sclerosis and spinal cord injury.

Mechanism: Arbaclofen, or R-baclofen, acts upstream of the mGluR5 receptor to increase inhibitory neurotransmission. It is the isomer of baclofen which harbors antispastic activity.
Curator reviewed
Primary indication: Investigated in clinical trials as a potential treatment for spasticity in multiple sclerosis, autism spectrum disorder, and social withdrawal in fragile X syndrome.Curator reviewed
Formula / weight: C₁₀H₁₂ClNO₂ · 213.661 g/mol (avg)
Also known as: (R)-Baclofen
Code names: OS440 · STX-209

Resolves to

Compound

UNIINYU6UTW25BCAS69308-37-8ChEMBLCHEMBL301742PubChem44602

Structure

InChIKeyKPYSYYIEGFHWSV-QMMMGPOBSA-NSMILES[H][C@@](CN)(CC(O)=O)C1=CC=C(Cl)C=C1

Targets

Q9UBS5GABBR1O75899GABBR2

What you can answer from here — as of February 21, 2021

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

18Clinical trialsPhase, status and sponsor resolved per trial

21+ReferencesStructured and connected to the statements they support

Which drugs share a target with Arbaclofen, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account